Abbreviated kinetic profiles in area-under-the-curve monitoring of cyclosporine therapy Technical Note by Gaspari, Flavio et al.
Abbreviated kinetic profiles in area-under-the-curve monitoring
of cyclosporine therapy
Technical Note
FLAVIO GASPARI, NORBERTO PERICO, ORIETTA SIGNORINI, RAFFAELE CARUSO, and GIUSEPPE REMUZZI
Department of Transplant Immunology and Innovative Antirejection Therapies, Ospedali Riuniti Bergamo - Mario Negri Institute for
Pharmacological Research, Bergamo, Italy
Abbreviated kinetic profiles in area-under-the-curve monitoring
of cyclosporine therapy. Technical Note.
Background. The new microemulsion formulation of cyclospor-
ine (CsA-ME) displays more consistent pharmacokinetic proper-
ties than the original formulation and may allow successful
implementation of an abbreviated area-under-the-curve (AUC)
strategy.
Methods. Here we compared two limited sampling strategies in
order to define the one that best predicts AUC after CsA-ME in
51 renal transplant recipients with stable renal function. Pharma-
cokinetics were based on analysis of blood samples collected over
12 hours after drug administration by high-performance liquid
chromatography (HPLC). Predicted AUC was estimated by using
a three-point (0, 1 and 3 hr) or a two-point (2 and 6 hr or 0 and
2 hr) sampling strategy.
Results. A simplified strategy with three time points of blood
collection at 0, 1, and 3 hours after CsA-ME allowed adequate
and accurate prediction of the daily exposure to CsA. AUC
prediction with two-point sampling at 2 and 6 hours was less good
with a very large error in prediction (only 59% of the estimated
AUC were within the accepted range). This limitation was even
more evident when the 0 and 2 hour time points were examined,
in which only 51% of AUC estimates were included in the
accepted range of variation (210 to 10%).
Conclusions. A limited strategy of three-point sampling taken
early after dosing allows an excellent and perfectly reliable
prediction of the actual AUC.
In the last decade cyclosporine (CsA) has become a key
factor in immunosuppressant combinations to prevent or-
gan transplant rejection [1–4], and has contributed to
improved graft survival rates and overall clinical outcome
[5]. The clinical use of CsA, however, is hindered by its
pharmacokinetic variability [6], which requires close mon-
itoring of blood levels to avoid either toxicity or underdos-
ing. Two drug monitoring strategies have been used: trough
concentration or full pharmacokinetic profiles (area-under-
the-curve, AUC) [7]. Trough concentrations are helpful in
extreme cases of poor gastrointestinal absorption or rapid
drug metabolism, but are of limited value to predict adverse
events or the actual exposure to the drug. AUC, which is
calculated by the trapezoidal method from blood CsA
concentrations derived from a full six or twelve time-point
pharmacokinetic profile during 12 hours post-dosing, pro-
vides a superior index of CsA exposure [8], but is seldom
used since blood samples must be obtained at precise times,
and the need for multiple drug concentration measure-
ments is unacceptably expensive for routine use. Abbrevi-
ated AUC profiles have been proposed, but data obtained
thus far have been inconsistent due to a lack of correlation
between the predicted and measured CsA AUC, when a
limited sampling strategy was used [9]. Moreover, the
necessity for late time-points compromised the utility of the
abbreviated strategy because of the prolonged period of
sampling. Major over- and underestimation of the real
AUC values was the consequence of the erratic absorptive
process of the conventional CsA formulation, Sandimmune
[10–12]. The new microemulsion formulation of CsA
(CsA-ME; Neoral) displays more consistent pharmacoki-
netic properties than the original formulation, and may
therefore allow the successful implementation of an abbre-
viated AUC strategy [13]. By using a step-wise regression
analysis, we have recently shown that a three-point sam-
pling strategy (0, 1 and 3 hr after CsA-ME dosing) reliably
predicts the actual AUC [14]. Other studies have favored a
two-time sample strategy after drug dosing, that is, sam-
pling at 2 and 6 hours or at baseline (0) and 2 hours [15, 16].
The present study was designed to compare two limited
sampling strategies and determine which one best predicts
AUC after CsA-ME administration. This would possibly
contribute to maximizing the information that can be
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derived from CsA monitoring in the routine outpatient
clinic.
METHODS
Patients
Fifty-one outpatients (11 female, 40 male; mean age 39
years) regularly followed at the Unit of Nephrology of the
Department of Transplant Immunology and Innovative
Antirejection Therapies, Ospedali Riuniti Bergamo -
Mario Negri Institute for Pharmacological Research, Ber-
gamo, Italy, who had received kidney transplant at least six
months prior to the study, were involved. Twenty of these
patients were previously studied to derive the three point
equation to estimate AUC [14]. Patients had a kidney
transplant for at least six months (mean 20 months) and
had stable renal function, as documented by changes in
creatinine clearance of less than 20% over the last three
months before the trial. They were on triple immunosup-
pressive theraphy with CsA, steroids, and azathioprine, and
received their daily oral CsA (range 1.5 to 4.2 mg/kg) in two
divided doses.
Study protocol
We analyzed 81 serial 12-hour CsA pharmacokinetic
profiles after the morning dose of the new microemulsion
formulation, CsA-ME. The pharmacokinetics were based
on analysis of blood samples collected from the antecubital
vein at 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12 hours
after drug administration. Blood samples were analyzed by
high-performance liquid chromatography (HPLC) as pre-
viously described [14]. The area under the blood concen-
tration curve from time equals zero to the last sampling
point (12 hr) (AUC0312) was calculated by trapezoidal
rule. Predicted AUC after CsA-ME administration was
estimated by using a three-point sampling strategy (at
sampling points 0, 1, and 3 hr after CsA-ME dosing)
defined by:
AUC 5 5.189 3 @0 hours# 1 1.267 3 @1 hour#
1 4.150 3 @3 hours# 1 135.079
as previously described [14]. The equation was derived
after multiple and stepwise regression analyses carried out
using AUC as the dependent variable, and the blood
concentrations grouped by time as the independent vari-
ables.
We also tested the equations proposed by other authors
for an ability to predict the full AUC obtained in our
patients by using a two-point sampling strategy. Thus, for
the AUC estimate we used the equations proposed by (a)
Amante and Kahan [15]
AUC 5 2.4 3 @2 hours# 1 7.7 3 @6 hours# 1 195.8
and (b) Keown et al [16]
AUC 5 12.34 3 @0 hours# 1 2.48 3 @2 hours#
1 441.42
Additionally, we compared the three point estimation with
our own equations derived for the 2 and 6 hour or 0 and 2
hour strategies. For the 2 and 6 hour sampling points:
AUC 5 1.963 3 @2 hours# 1 8.697 3 @6 hours#
1 397.510
and for the 0 and 2 hour sampling points:
AUC 5 8.770 3 @0 hours# 1 3.070 3 @6 hours#
1 363.078
Agreement between the predicted and measured AUC was
estimated using regression analysis, and the prediction
error was calculated as:
% prediction error 5 ~predicted AUC
2 measured AUC)/measured AUC 3 100
The frequency of percent error in AUC prediction was
ranked and plotted by using a histogram graphic according
to 5% intervals. An error in prediction from the 210% to
10% interval was considered acceptable. Statistical signifi-
cance was defined as P , 0.05.
RESULTS
Figure 1 shows the correlation between the full and
abbreviated AUC measured according to three or two
sampling points. Applying a three-point strategy (0, 1 and 3
hr after CsA-ME dosing) the regression analysis docu-
mented a highly significant (P , 0.001) correlation between
measured and predicted AUC (r 5 0.980; Fig. 1A). Corre-
lation analysis using a two-point (2 and 6 hr) equation for
predicting AUC gave more disperse values around the line
of identity, despite a still significant regression value (r 5
0.926, P , 0.001; Fig. 1B) as compared to the full AUC.
Similarly, the two point strategy with sampling at 0 and 2
hours post-CsA-ME dosing provided a highly significant
correlation between measured and predicted AUC (r 5
0.890, P , 0.001; Fig. 1C).
Calculating the mean and the 95% confidence interval
(C.I.) for the above data, a further index of the validity of
the above equations, the analysis for the three-point sam-
pling equation gave a very narrow C.I., but with the zero
error value outside the interval (CI, 2.2 to 4.8; average
error 3.5 6 5.9%). With the two-point equations the zero
error value was still outside the interval, but data were
more scattered, as documented by a larger confidence
interval for both the 2 and 6 hour (CI, 25.7 to 20.8;
average error 23.3 6 11.1%) and 0 and 2 hour (CI, 2.0 to
8.5; average error 5.2 6 14.6%) sampling points.
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Figure 2 reports the distribution of percent error in AUC
prediction with the three strategies. Using the three-point
sampling equation the associated error in AUC prediction
ranged from 210.3% to 18.1%. The error in prediction was
minimal since 89% of the AUC estimations were within the
210 to 110% variation, and only nine determinations were
outside this range. With the 2 and 6 hour sampling point
equation a very large error in AUC prediction was found
(range, 228.9% to 26.2%). In this instance only 59% of the
estimated AUC were within the accepted range. When the
0 and 2 hour time-point equation values were examined,
the error in AUC prediction ranged from 231.5% to 50%,
and 51% of the AUC estimations were included in the 210
to 110% variation as compared to the measured AUC.
When a similar analysis was performed by using our own
equations derived for the 2 and 6 hour strategy, again a very
large error in AUC prediction was reported (range,
226.2% to 30.3%), only 64% of the estimated AUC being
within the accepted range. Comparable results were ob-
tained with the 0 and 2 hour approach: the error in AUC
prediction ranged from 231.8% to 37.1%, and only 54% of
the AUC estimations were included in 210% to 10%
variation.
DISCUSSION
We have shown that a simplified strategy with three time
points of blood collection at 0, 1 and 3 hours after CsA-ME
administration allows adequate and accurate prediction of
the daily exposure to CsA of kidney transplant patients
given the microemulsion formulation as a part of their
immunosuppressive therapy. This finding confirms our
previous observation in a smaller number of AUC estima-
tions in which a highly significant correlation coefficient
between measured and predicted AUC was documented
with a limited error in the prediction [14]. Prediction of
CsA AUC using a limited three sampling strategy in
patients given the CsA microemulsion formulation has also
been proposed by Foradori and coworkers [17], who found
a high correlation (r 5 0.910) between measured and
predicted AUC with sampling at 1, 2.5 and 5 hours after
dosing. This approach is, however, less comfortable for the
patient, given the time of the last blood sampling required.
Other investigators have documented the best AUC pre-
diction with blood sampling at 0, 1 and 2 hours in patients
receiving CsA-ME [18]. However, when we applied the
equation derived from the above-mentioned study to our
patients, we found a very large associated error in AUC
prediction [14], which makes this approach unreliable.
More recently, Amante and Kahan analyzed the AUC
profiles from 15 primary cadaveric kidney transplant recip-
ients during their first post-transplant month [15]. By
multiple regression analysis these authors found the best
correlation between the full versus the abbreviated AUC
with the two-sampling points at 2 and 6 hours (r 5 0.965)
after CsA-ME dosing. According to the Amante and
Kahan, this blood sampling strategy offers the advantage of
avoiding the bias of the trough point blood sampling (the
minimum CsA concentration 12 hr after the evening dose
of the drug) that is related to the substantial variability in
the timing of self-administration of CsA by patients [19].
We analyzed our data according to the model equation
proposed by Kahan, but the AUC prediction was less good.
Moreover, the correlation coefficient with this two-point
sampling strategy was numerically lower as compared to
the three-point sampling at 0, 1 and 3 hours after CsA-ME
dosing. The discrepancy may be the consequence of the
analysis performed on different sets of data and/or related
to differences in the analytical method employed for CsA
blood determination (HPLC vs. fluorescence polarization
immunoassay, FPIA). The FPIA method overestimates
CsA concentrations because it detects drug metabolites of
limited biological activity [20], thus producing a bias that
Fig. 1. Correlation between measured and predicted AUC using three different blood sampling strategies. (A) y 5 0.989x 1 126; r 5 0.980; N 5 81.
(B) y 5 0.887x 1 215; r 5 0.926; N 5 81. (C) y 5 0.796x 1 702; r 5 0.890; N 5 81.
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may vitiate the correlation of the 2 and 6 hour CsA
concentrations with full AUC exposure. Moreover, the
greater pharmacokinetic consistency of the CsA-ME and
the characteristic of the pharmacokinetic profile obtained
with this microemulsion formulation, which invariably re-
sults in CsA blood level at 10 hours after dosing compara-
ble to trough concentration (99 6 32 and 98 6 26 ng/ml,
respectively), would overwhelm the concern about possible
bias of trough point blood sampling.
On the other hand, although substantially easier than the
full kinetic analysis, the use of a 2 and 6 hour time-point
sampling method for predicting AUC remains time con-
suming and therefore impractical for routine clinical mon-
itoring. Regression analyses have recently shown that the
limited-sampling strategy could be substantially simplified,
while retaining a high degree of correlation with CsA
exposure, by using only a two-point protocol in which blood
samples were taken at 0 and 2 hours after dosing [16]. We
have also analyzed our CsA concentration data using the
model equation of the 0 and 2 hour sampling points.
Although in this case the correlation coefficient between
measured and predicted AUC was very similar to that
obtained with 0, 1 and 3 time-points after CsA-ME dosing,
the associated error in AUC prediction was wider. When
one compares two methods for evaluating AUC, the agree-
ment between the two is usually evaluated by calculating
the correlation coefficient (r). However, r does not measure
the agreement but only the strengh of a relationship
between two variables. Actually, the correlation depends
on the range of values considered for the analysis, and data
with a quite high correlation may be in poor agreement
[21]. Thus, given the large limit of agreement, expressed by
the wide error in prediction of the 0 and 2 hour time-point
strategy, this abbreviated estimation of AUC seems less
reliable than the three-point sampling approach. This is
consistent with data of a preliminary study in routine
clinical use by other investigators [19] in which AUC
estimates based on drug concentration in samples obtained
at 0 and 2 hours after CsA-ME administration were clearly
less reliable than the estimate from the 2 and 6 hour values.
These findings can be attributed to the fact that 0 and 2
hour blood concentrations reflect the minimum and maxi-
mum levels of CsA exposure with the microemulsion
formulation, whereas 0, 1 and 3 hour sampling also include
most of the absorption and distribution phases of the
pharmacokinetic profile of the drug, thus more closely
predicting the full AUC.
Moreover, even when AUC were predicted by using our
own two point equations derived from CsA blood concen-
trations determined by HPLC (either the 2 and 6 hr or the
0 and 2 hr post-dosing), large errors in prediction were
reported. This further indicates that the errors in AUC
prediction are due to the inadequacy of the two-point
sampling model rather than to the analytical method (FPIA
or HPLC) in determining CsA blood concentration.
The possibility also exists that differences between the
North American transplant patient population (30% black,
30% diabetics) and North Italy population (Caucasian)
Fig. 2. Frequency distribution of error in AUC prediction. Shaded area
represents the interval of acceptance error (210% to 10%).
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may account for the discrepancy between our three-point
estimate and the 2 and 6 hour or 0 and 2 hour sampling
strategies proposed by Amante and Kahan [15] and Keown
et al [16], respectively. However, the large error in AUC
prediction obtained with our two-point equations suggests
that the limitation of the two-point strategy is intrinsic to
the methods and not related to racial differences in the
population studied.
The possibility of estimating the CsA AUC within a
reasonable percentage of error (less than 10%) by using
only three very early blood samples after CsA-ME dosing
indicates that, with this novel CsA formulation, drug ther-
apy and patient exposure to the drug could be monitored
accurately with minimum effort, at least late (more than 6
months) after transplantation. Indeed, three blood samples
collected within three hours after CsA-ME administration
are definitely more comfortable for the patient because he
or she can save time and, more importantly, the physician
can reduce the total amount of blood collected compared
with the complete pharmacokinetic profile. This strategy is
also less taxing for the transplant center in terms of the
effort of the staff to provide blood sampling, sample
analysis and overall results, which in turn substantially
reduces costs.
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